Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry--exploring preferred orientation effects.

[1]  G A Stephenson,et al.  Characterization of the solid state: quantitative issues. , 2001, Advanced drug delivery reviews.

[2]  M. Kemper,et al.  Quantitative analysis of polymorphs in binary and multi-component powder mixtures by near-infrared reflectance spectroscopy. , 2000, International journal of pharmaceutics.

[3]  J. Rollinger,et al.  Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. , 2000, Journal of pharmaceutical sciences.

[4]  M. Kemper,et al.  Quantifying Crystalline Form Composition in Binary Powder Mixtures Using Near-Infrared Reflectance Spectroscopy , 2000, Pharmaceutical development and technology.

[5]  T. Rades,et al.  Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride. , 1999, International journal of pharmaceutics.

[6]  G. Zografi,et al.  The Quantitative Analysis of Crystallinity Using FT-Raman Spectroscopy , 1998, Pharmaceutical Research.

[7]  J. Sjöblom,et al.  Quantitative FT-Raman analysis of two crystal forms of a pharmaceutical compound. , 1997, Journal of pharmaceutical and biomedical analysis.

[8]  P. Schroeder,et al.  Accurate quantification of quartz and other phases by powder X-ray diffractometry , 1997 .

[9]  C. Kontoyannis,et al.  Use of Raman Spectroscopy for the Quantitative Analysis of Calcium Oxalate Hydrates: Application for the Analysis of Urinary Stones , 1997 .

[10]  D. Bugay,et al.  Quantitation of cefepime.2HCl dihydrate in cefepime.2HCl monohydrate by diffuse reflectance IR and powder X-ray diffraction techniques. , 1996, Journal of pharmaceutical and biomedical analysis.

[11]  P. Gao.  Determination of the Composition of Delavirdine Mesylate Polymorph and Pseudopolymorph Mixtures Using 13C CP/MAS NMR , 1996, Pharmaceutical Research.

[12]  Rumi Faizer,et al.  Quantification of crystallinity in blends of lyophilized and crystalline MK-0591 using x-ray powder diffraction , 1995 .

[13]  Stephen Byrn,et al.  Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations , 1995, Pharmaceutical Research.

[14]  J. Miller,et al.  Statistics for Analytical Chemistry , 1993 .

[15]  R. Suryanarayanan,et al.  Quantitative analysis of the active ingredient in a multi-component tablet formulation by powder X-ray diffractometry , 1991 .

[16]  R. Suryanarayanan.  Determination of the Relative Amounts of Anhydrous Carbamazepine (C15H12N2O) and Carbamazepine Dihydrate (C15H12N2O · 2H2O) in a Mixture by Powder X-ray Diffractometry , 1989, Pharmaceutical Research.

[17]  R. Chao,et al.  Polymorphism of l,2-Dihydro-6-neopentyl-2-oxonicotinic Acid: Characterization, Interconversion, and Quantitation , 1987, Pharmaceutical Research.

[18]  F. J. Holler,et al.  Principles of Instrumental Analysis , 1973 .

[19]  B. Cullity,et al.  Elements of X-ray diffraction , 1957 .

[20]  L. Alexander,et al.  Basic Aspects of X-Ray Absorption In Quantitative Diffraction Analysis of Powder Mixtures , 1948, Powder Diffraction.

[21]  C. Kontoyannis,et al.  Quantitative Analysis of Sulfated Calcium Carbonates Using Raman Spectroscopy and X-ray Powder Diffraction , 1997 .

[22]  Raymond C Rowe,et al.  Handbook of Pharmaceutical Excipients , 1994 .

[23]  L. Alexander,et al.  X-Ray diffraction procedures for polycrystalline and amorphous materials , 1974 .